United Therapeutics

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. The company was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

United Therapeutics achieves record 2022 performance, eyes revenue doubling

United Therapeutics had a remarkable year in 2022, with strong financial performance and market acceptance of its products. While facing challenges and questions from analysts, UTHR remains focused on growth and innovation.

United Therapeutics reports robust Q1 growth and eyes new opportunities

United Therapeutics (UTHR) showcased strong revenue growth, product performance, and strategic investments in manufacturing facilities and pipeline trials. Challenges include managing factors affecting Tyvaso revenue and patient flow between key products. However, opportunities from new FDA approvals and organ manufacturing advancements position UTHR for continued growth and innovation.

United Therapeutics achieves record revenue, eyes growth beyond hypertension

United Therapeutics delivered exceptional financial performance in Q2 2023, driven by strong revenue growth and strategic product positioning.
The company's focus on combination therapies, expansion into new markets, and commitment to innovation position it well for future success.
Challenges in market saturation and limited drug options in certain therapeutic areas require targeted strategies and continued R&D efforts for sustained growth.
Overall, United Therapeutics' Q2 performance reflects a balance of strengths, challenges, and opportunities that shape its trajectory in the healthcare sector.

United Therapeutics reports record Q3 revenue and growth opportunities

United Therapeutics had a robust Q3 performance with record revenue and growth, driven by strong performance in the Tyvaso franchise. The company is strategically positioned for growth across its commercial business, pipeline programs, and organ technologies. While facing competition and trial challenges, UTHR remains optimistic about its growth potential and opportunities in addressing critical medical needs.

United Therapeutics reports record revenue growth and highlights innovative pipeline

United Therapeutics (UTHR) delivered a strong performance in Q4 2023, showcasing record revenue growth and confidence in its product portfolio. While facing challenges like patient demand fluctuations and potential competition, UTHR remains focused on innovation and growth opportunities in its pipeline.

United Therapeutics reports record revenue and advances in organ manufacturing

United Therapeutics (UTHR) delivered strong financial performance in Q1 2024, driven by revenue growth and strategic capital allocation initiatives.
The company's focus on product innovation, clinical advancements, and organ manufacturing positions UTHR well for future growth and market competitiveness.
While facing challenges in market penetration and product integration, UTHR has opportunities to expand its market presence, enhance treatment options, and pioneer advancements in organ transplantation.

United Therapeutics (UTHR) reports record revenue and strategic growth

United Therapeutics (UTHR) delivered a strong performance in Q2 2024, driven by record revenue and strategic product focus. The company's emphasis on innovation, market competitiveness, and employee satisfaction positions it well for future growth. Challenges in navigating market dynamics and executing key studies require focused attention, while opportunities exist in expanding market share and optimizing capital allocation.

United Therapeutics reports record revenue growth, faces litigation challenges

United Therapeutics delivered a strong performance in Q3 2024, achieving record revenue and significant growth in key product segments.
While facing challenges such as litigation accrual and slower growth in certain product revenues, the company remains well-positioned for future opportunities.
Investors have shown confidence in United Therapeutics, as reflected in the stock appreciation post ASR program, indicating positive market sentiment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Franklin Resources

Tapestry

Bernard Horn (Trades, Portfolio), manager of the Polaris Global Value Fund, disclosed last week that his firms top five trades during the first quarter included new positions in United Therapeutics Corp. ( UTHR , Financial) and Marubeni Corp. ( TSE:8002 , Financial) and the sale of its holdings in Tapestry Inc. ( TPR , Financial), Franklin Resources Inc. ( BEN , Financial) and Signature Aviation PLC ( LSE:SIG , Financial).

Bernard Horn's Top 5 Trades of the 1st Quarter

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference

United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.

United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q1 2021 Results - Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of -76.54% and 3.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Lags Q1 Earnings Estimates

United Therapeutics Corporation Reports First Quarter 2021 Financial Results

United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021

United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA

United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.

United Therapeutics (UTHR) Gains on Tyvaso Label Expansion

Will future Tyvaso revenue growth push United Therapeutics to new heights?

This Pharma Can Breathe New Life Into Your Portfolio

The stock price of United Therapeutics Corporation (Nasdaq: UTHR) increased by over 10% pre-market. This is why it happened.

United Therapeutics Stock Price Increased Over 10% Pre-Market: Why It Happened

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C.

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Why Is United Therapeutics (UTHR) Down 0.3% Since Last Earnings Report?

United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum

United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference

Based on the FDA's written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the development of Trevyent. Trevyent is a drug-device combination product that combines two-day, single-use, disposable PatchPump technology with treprostinil for the subcutaneous treatment of pulmonary arterial hypertension.

United Therapeutics Pulls Plug On Trevyent Development

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's...

United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q4 2020 Results - Earnings Call Transcript

United Therapeutics (UTHR) delivered earnings and revenue surprises of -26.26% and 8.12%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Misses Q4 Earnings Estimates

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2020. Full year net revenue rose to $1,483 million, as U.S. patients...

United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q4 Release

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2020 financial results before the market opens on Wednesday, February 24, 2021. United...

United Therapeutics Corporation To Report Fourth Quarter And Full Year 2020 Financial Results Before The Market Opens On Wednesday, February 24, 2021

UTHR is progressing with its next-generation dry powder formulation, Tyvaso DPI, towards the market. It plans to file an NDA under priority review in April 2021.

United Therapeutics In Pulmonary Arterial Hypertension

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that that the BREEZE study of Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients...

News for United Therapeutics Stock (UTHR)